Skip to main content
Premium Trial:

Request an Annual Quote

Personalized Medicine's New Promise: More M&A

A Dow Jones Newswires story covers personalized medicine with profiles of companies, including Sequenom and Helicos, that push diagnostic tests for biomarkers. It's the expected growth in this arena that led to Invitrogen's $6.7 billion acquisition of Applied Biosystems, the article says; more deals are likely in the offing. The story quotes analyst Arthur Henderson as saying, "There is a lot of competition for deals; it is going to increase. ... The sky is the limit in terms of opportunity."

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.